Drug intelligence / Profile preview

STC4010

Development stage: Preclinical
Lead developer: Staidson Biopharmaceutical
Modality: Small Molecules

Overview

STC4010 is a small molecule therapeutic candidate being developed by Staidson Pharma (specifically Staidson Hongkong) for the treatment of gout and hyperuricemia. As of early 2024, the program is in the IND-enabling phase of development. The drug is designed to manage elevated serum uric acid levels, a hallmark of gout, although its specific molecular target and mechanism of action have not been publicly disclosed by the developer. It is part of Staidson's metabolic disease pipeline, which focuses on addressing unmet needs in inflammatory and metabolic conditions.

Beyond the preview

Go deeper on STC4010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC4010.

Explore the full profile